The guidance cut reflects a material deceleration in second-line ATTR-CM demand after initial pent-up launch surge. Traders should monitor upcoming quarterly demand trends and any competitive responses from Pfizer's tafamidis. The raised collaboration/royalty guidance partially offsets but does not change the negative read-through for the core TTR franchise.
Drugs in focus
ALNY drug pipeline →brezosiran
● Neutral Named in this 8-K- Impact
- Phase
- Phase 1b
- Time to market
- If the pivotal study begins in 2027 as planned, a potential approval would be several years away, likely 2029-2031 assuming positive Phase 3 data and a standard FDA review timeline.
- Next catalyst
- None dated
What to watchThe next catalyst for brezosiran is the planned initiation of a placebo-controlled pivotal study in 2027, pending regulatory alignment. Positive Phase 1b data (60-64% mean mHTT reduction) supports advancement, but the drug is still early-stage and represents a small part of Alnylam's diversified, approved-product portfolio. Watch for regulatory feedback and trial design details in 2027.
- ● GIVLAARI 3/10 Approved (FDA approval 2019-11-20) Named in filing
- ● ONPATTRO 3/10 Approved (marketed); Phase 3 (APOLLO-B) completed Named in filing
- ● OXLUMO 3/10 Approved Named in filing
- ● ALN-6222 2/10 unknown (no registered ClinicalTrials.gov record found; appears to be an early, minimally disclosed pipeline program) Named in filing
- ● ALN-2232 1/10 Named in filing
- 1 more · All ALNY drugs, catalysts & trials →
How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 30 $205.48entry
- T+1 · 4mo ago +0.02%α −0.69% · $205.52
- T+5 · 3mo ago +5.18%α +1.56% · $216.12
- T+20 · 3mo ago +15.13%α +11.16% · $236.56
- T+60 · 25d ago +9.03%α +6.56% · $224.03
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Alnylam reported Q2 2026 non-GAAP diluted EPS of $1.84 (missed consensus of $2.15 by 14.5%) and total revenue of $1.291B (missed $1.32B consensus by 2.2%). The company lowered its full-year 2026 TTR net product revenue guidance from $4.4B-$4.7B to $4.2B-$4.5B, citing normalization of second-line demand after an initial pent-up launch surge. Despite strong 74% YoY product revenue growth, the guidance cut and earnings miss signal a slower-than-expected ATTR-CM launch trajectory.
Key Financial Metrics
Key Facts
- Q2 2026 total revenues $1.291B (+67% YoY), net product revenues $1.172B (+74% YoY)
- GAAP diluted EPS $1.21; non-GAAP diluted EPS $1.84 (missed consensus of $2.15 by 14.5%)
- Total TTR net product revenues $1.030B (+89% YoY), driven by AMVUTTRA sales of $1.012B (+106% YoY)
- Full-year 2026 TTR revenue guidance lowered to $4.2B-$4.5B from $4.4B-$4.7B; total product revenue guidance lowered to $4.7B-$5.1B from $4.9B-$5.3B
- Collaboration and royalty guidance raised to $575M-$625M from $400M-$500M
- Cash and marketable securities $3.3B as of June 30, 2026
Financial Impact
Full-year 2026 TTR revenue guidance cut by $200M at midpoint ($4.55B to $4.35B); total product revenue guidance cut by $200M at midpoint ($5.1B to $4.9B)
Risk Factors
- Slower-than-expected ATTR-CM market growth or increased competition
- Further downward revisions if second-line demand continues to normalize
- Pipeline setbacks in key programs (zilebesiran, nucresiran, mivelsiran)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001178670-26-000060 |
| Document: alny-20260730.htm | 0001178670-26-000060 |
| Document: 0001178670-26-000060-index-headers.html | 0001178670-26-000060 |
| Document: 0001178670-26-000060-index.html | 0001178670-26-000060 |
| Document: 0001178670-26-000060.txt | 0001178670-26-000060 |
| 8-K Data (Synthetic) | 0001178670-26-000060 |
Track record
15 reports on ALNY
1 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +26.35% at T+5 after the Oct 23, 2026 report. 1 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $160.53 Now $159.73 −0.50% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $165.50 Now $159.73 −3.49% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $165.04 Now $159.73 −3.22% settles Nov 20
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $165.04 Now $159.73 −3.22% settles Nov 20
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $156.66 to $156.65 Now $159.73 +1.96% ▼ −0.01% −3.30% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $156.66 to $156.65 Now $159.73 +1.96% ▼ −0.01% −3.30% vs SPY
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $165.00 to $155.94 Now $159.73 −3.19% ▼ −5.49% −2.79% vs SPY
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $174.00 to $156.66 Now $159.73 −8.20% ▼ −9.97% −5.24% vs SPY
- Oct 23, 202624d ago Institutional Cluster Bearish 4/10 Entry $224.03 to $165.00 Now $159.73 +28.70% ▲ +26.35% +25.79% vs SPY
- Aug 17, 202613w ago Court Ruling Neutral 4/10 Entry $228.61 to $240.08 Now $159.73 −30.13% ▲ +5.02% +5.22% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers